Company

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte
Auto-immuneChina Medical System

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

China Medical System Holdings Limited (CMS) (HKG: 0867; SGX: 8A8) announced that its subsidiary, Rxilient Medical, has obtained approval from the Health Sciences Authority (HSA) of Singapore for a new…

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

Zuellig Pharma Acquires Licensed Pharmaceutical Entity and Facility in Hangzhou, China – Strategic Move Strengthens Clinical Trial Sourcing Capabilities

Zuellig Pharma Acquires Licensed Pharmaceutical Entity and Facility in Hangzhou, China – Strategic Move Strengthens Clinical Trial Sourcing Capabilities

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Basecare MedicalHKG: 2170

Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market

BiosimilarsBoan Biotechnology

Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications

DiabetesEli Lilly

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

BiosimilarsCancer

Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China

Show More